RxDoctor Payments Data

Penner Schraudenbach, MD

Urology · Tomball, TXNPI 1477738409

Payments from drug & device makers

$35,299in general payments, 2019–2025

Across 670 payments — averaging $52.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$12K
  • Axonics, Inc.$8K
  • Boston Scientific$3K
  • Ferring Pharmaceuticals Inc.$3K
  • Medtronic$2K
  • Sumitomo Pharma America, Inc.$1K
  • plus $6K from 49 others

What the payments were for

  • Consulting fees$3,67510%
  • Speaking & faculty fees$10,91531%
  • Travel & lodging$1,7825%
  • Food & beverage$18,52452%
  • Education$4031%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$35,299 in reported general payments places this provider in the 85th percentile of 878 urology providers in Texas.

See all urology providers in Texas

Medicare billing

Part B allowed, 2024
$630,064
Medicare patients
816
Services billed
9,914

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron641$471,718
MyrbetriqMirabegron140$111,559
Solifenacin Succinate314$18,467
Tamsulosin Hcl1,176$17,379
Testosterone Cypionate261$15,177
Finasteride930$13,058
Oxybutynin Chloride ErOxybutynin Chloride542$11,589
Methenamine Hippurate102$7,029
Silodosin67$6,025
Estradiol61$3,250
Dutasteride117$2,796
Testosterone24$2,565
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen190$1,225
Alfuzosin Hcl ErAlfuzosin Hcl50$1,182
Cefdinir93$1,048

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$1,372$471,718641 claims
Astellas Pharma US IncMyrbetriq$11,935$111,559140 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 878 urology providers in Texas.

Other urology in Tomball

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →